165 related articles for article (PubMed ID: 36715063)
1. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
Ramsey LB; Prows CA; Chidambaran V; Sadhasivam S; Quinn CT; Teusink-Cross A; Tang Girdwood S; Dawson DB; Vinks AA; Glauser TA
Am J Health Syst Pharm; 2023 Jun; 80(13):852-859. PubMed ID: 36715063
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
3. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB; Ong HH; Schildcrout JS; Shi Y; Tang LA; Hicks JK; El Rouby N; Cavallari LH; Tuteja S; Aquilante CL; Beitelshees AL; Lemkin DL; Blake KV; Williams H; Cimino JJ; Davis BH; Limdi NA; Empey PE; Horvat CM; Kao DP; Lipori GP; Rosenman MB; Skaar TC; Teal E; Winterstein AG; Owusu Obeng A; Salyakina D; Gupta A; Gruber J; McCafferty-Fernandez J; Bishop JR; Rivers Z; Benner A; Tamraz B; Long-Boyle J; Peterson JF; Van Driest SL;
JAMA Netw Open; 2020 Dec; 3(12):e2029411. PubMed ID: 33315113
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial.
Mosley SA; Cicali E; Del Cueto A; Portman DG; Donovan KA; Gong Y; Langaee T; Gopalan P; Schmit J; Starr JS; Silver N; Chang YD; Rajasekhara S; Smith JE; Soares HP; Clare-Salzler M; Starostik P; George TJ; McLeod HL; Fillingim RB; Hicks JK; Cavallari LH
Pharmacotherapy; 2023 Dec; 43(12):1286-1296. PubMed ID: 37698371
[TBL] [Abstract][Full Text] [Related]
6. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
8. The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK; Somogyi AA; Rubio J; Philip J
Curr Treat Options Oncol; 2022 Oct; 23(10):1353-1369. PubMed ID: 36001223
[TBL] [Abstract][Full Text] [Related]
9. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
10. Use of pharmacogenetic data to guide individualized opioid prescribing after surgery.
Rocco R; Thiels CA; Ubl DS; Moyer AM; Habermann EB; Cassivi SD
Surgery; 2019 Oct; 166(4):476-482. PubMed ID: 31320226
[TBL] [Abstract][Full Text] [Related]
11. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Thomas CD; Parvataneni HK; Gray CF; Deen JT; Prieto HA; Pulido LF; Elsey AR; Elwood EN; Starostik P; Gong Y; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2021 Apr; 23(4):621-628. PubMed ID: 33420349
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.
Agulló L; Aguado I; Muriel J; Margarit C; Gómez A; Escorial M; Sánchez A; Fernández A; Peiró AM
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445931
[TBL] [Abstract][Full Text] [Related]
15. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.
Cavallari LH; Cicali E; Wiisanen K; Fillingim RB; Chakraborty H; Myers RA; Blake KV; Asiyanbola B; Baye JF; Bronson WH; Cook KJ; Elwood EN; Gray CF; Gong Y; Hines L; Kannry J; Kucher N; Lynch S; Nguyen KA; Obeng AO; Pratt VM; Prieto HA; Ramos M; Sadeghpour A; Singh R; Rosenman M; Starostik P; Thomas CD; Tillman E; Dexter PR; Horowitz CR; Orlando LA; Peterson JF; Skaar TC; Van Driest SL; Volpi S; Voora D; Parvataneni HK; Johnson JA;
Clin Transl Sci; 2022 Oct; 15(10):2479-2492. PubMed ID: 35899435
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of pharmacogenetics in pain management.
Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
[TBL] [Abstract][Full Text] [Related]
18. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Mosley SA; Hicks JK; Portman DG; Donovan KA; Gopalan P; Schmit J; Starr J; Silver N; Gong Y; Langaee T; Clare-Salzler M; Starostik P; Chang YD; Rajasekhara S; Smith JE; Soares HP; George TJ; McLeod HL; Cavallari LH
Contemp Clin Trials; 2018 May; 68():7-13. PubMed ID: 29535047
[TBL] [Abstract][Full Text] [Related]
19. Provider specialty and odds of a new codeine, hydrocodone, oxycodone and tramadol prescription before and after the CDC opioid prescribing guideline publication.
Tucker J; Salas J; Zhang Z; Grucza R; Scherrer JF
Prev Med; 2021 May; 146():106466. PubMed ID: 33636196
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
